Seeking Alpha

Verastem (VSTM) hosts its annual research and development day. Highlights: VSTM says it plans to...

Verastem (VSTM) hosts its annual research and development day. Highlights: VSTM says it plans to have "three candidates in six clinical trials ongoing in parallel by the end of 2013"; Phase 1 portion of Phase 1/1b VS-6063 study is complete; "a significant decrease in the CA-125 biomarker in several patients" was observed; treatment is well tolerated in combination with paclitaxel, opening the door for exploring "this combination in a wide range of cancers."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)